200 related articles for article (PubMed ID: 26713839)
1. In Vitro and in Vivo Characterization of MOD-4023, a Long-Acting Carboxy-Terminal Peptide (CTP)-Modified Human Growth Hormone.
Hershkovitz O; Bar-Ilan A; Guy R; Felikman Y; Moschcovich L; Hwa V; Rosenfeld RG; Fima E; Hart G
Mol Pharm; 2016 Feb; 13(2):631-9. PubMed ID: 26713839
[TBL] [Abstract][Full Text] [Related]
2. Long-Acting C-Terminal Peptide-Modified hGH (MOD-4023): Results of a Safety and Dose-Finding Study in GHD Children.
Zelinska N; Iotova V; Skorodok J; Malievsky O; Peterkova V; Samsonova L; Rosenfeld RG; Zadik Z; Jaron-Mendelson M; Koren R; Amitzi L; Raduk D; Hershkovitz O; Hart G
J Clin Endocrinol Metab; 2017 May; 102(5):1578-1587. PubMed ID: 28323965
[TBL] [Abstract][Full Text] [Related]
3. MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults.
Strasburger CJ; Vanuga P; Payer J; Pfeifer M; Popovic V; Bajnok L; Góth M; Olšovská V; Trejbalová L; Vadasz J; Fima E; Koren R; Amitzi L; Bidlingmaier M; Hershkovitz O; Hart G; Biller BMK
Eur J Endocrinol; 2017 Mar; 176(3):283-294. PubMed ID: 27932411
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and Pharmacodynamic Modeling of MOD-4023, a Long-Acting Human Growth Hormone, in Growth Hormone Deficiency Children.
Fisher DM; Rosenfeld RG; Jaron-Mendelson M; Amitzi L; Koren R; Hart G
Horm Res Paediatr; 2017; 87(5):324-332. PubMed ID: 28399519
[TBL] [Abstract][Full Text] [Related]
5. Designing a long-acting human growth hormone (hGH) by fusing the carboxyl-terminal peptide of human chorionic gonadotropin beta-subunit to the coding sequence of hGH.
Fares F; Guy R; Bar-Ilan A; Felikman Y; Fima E
Endocrinology; 2010 Sep; 151(9):4410-7. PubMed ID: 20660071
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, Pharmacodynamics, and Safety of a Long-Acting Human Growth Hormone (MOD-4023) in Healthy Japanese and Caucasian Adults.
Kramer WG; Jaron-Mendelson M; Koren R; Hershkovitz O; Hart G
Clin Pharmacol Drug Dev; 2018 Jun; 7(5):554-563. PubMed ID: 29136343
[TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children.
Hou L; Chen ZH; Liu D; Cheng YG; Luo XP
Drug Des Devel Ther; 2016; 10():13-21. PubMed ID: 26719670
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, Pharmacodynamics, and Efficacy of a Novel Long-Acting Human Growth Hormone: Fc Fusion Protein.
Kim SJ; Kwak HH; Cho SY; Sohn YB; Park SW; Huh R; Kim J; Ko AR; Jin DK
Mol Pharm; 2015 Oct; 12(10):3759-65. PubMed ID: 26370910
[TBL] [Abstract][Full Text] [Related]
9. Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys.
Osborn BL; Sekut L; Corcoran M; Poortman C; Sturm B; Chen G; Mather D; Lin HL; Parry TJ
Eur J Pharmacol; 2002 Dec; 456(1-3):149-58. PubMed ID: 12450581
[TBL] [Abstract][Full Text] [Related]
10. A novel long-acting human growth hormone fusion protein (VRS-317): enhanced in vivo potency and half-life.
Cleland JL; Geething NC; Moore JA; Rogers BC; Spink BJ; Wang CW; Alters SE; Stemmer WP; Schellenberger V
J Pharm Sci; 2012 Aug; 101(8):2744-54. PubMed ID: 22678811
[TBL] [Abstract][Full Text] [Related]
11. Improving the pharmacokinetics/pharmacodynamics of prolactin, GH, and their antagonists by fusion to a synthetic albumin-binding peptide.
Langenheim JF; Chen WY
J Endocrinol; 2009 Dec; 203(3):375-87. PubMed ID: 19770179
[TBL] [Abstract][Full Text] [Related]
12. Nonclinical pharmacokinetic and pharmacodynamic characterisation of somapacitan: A reversible non-covalent albumin-binding growth hormone.
Thygesen P; Andersen HS; Behrens C; Fels JJ; Nørskov-Lauritsen L; Rischel C; Johansen NL
Growth Horm IGF Res; 2017 Aug; 35():8-16. PubMed ID: 28595133
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of a novel long-acting recombinant follicle stimulating hormone agonist by fusing Fc to an FSH-β subunit.
Zhang YL; Guo KP; Ji SY; Liu XM; Wang P; Wu J; Gao L; Jiang TQ; Xu T; Fan HY
Hum Reprod; 2016 Jan; 31(1):169-82. PubMed ID: 26621853
[TBL] [Abstract][Full Text] [Related]
14. Development of a sustained-release recombinant human growth hormone formulation.
Kwak HH; Shim WS; Choi MK; Son MK; Kim YJ; Yang HC; Kim TH; Lee GI; Kim BM; Kang SH; Shim CK
J Control Release; 2009 Jul; 137(2):160-5. PubMed ID: 19332090
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].
Hou L; Luo XP; Du ML; Ma HM; Gong CX; Li YC; Shen SX; Zhao ZH; Liang L; Dong GP; Yan CY; Du HW
Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383
[TBL] [Abstract][Full Text] [Related]
16. Fusing the carboxy-terminal peptide of the chorionic gonadotropin (CG) beta-subunit to the common alpha-subunit: retention of O-linked glycosylation and enhanced in vivo bioactivity of chimeric human CG.
Furuhashi M; Shikone T; Fares FA; Sugahara T; Hsueh AJ; Boime I
Mol Endocrinol; 1995 Jan; 9(1):54-63. PubMed ID: 7539107
[TBL] [Abstract][Full Text] [Related]
17. A novel sustained-release formulation of recombinant human growth hormone and its pharmacokinetic, pharmacodynamic and safety profiles.
Wei Y; Wang Y; Kang A; Wang W; Ho SV; Gao J; Ma G; Su Z
Mol Pharm; 2012 Jul; 9(7):2039-48. PubMed ID: 22663348
[TBL] [Abstract][Full Text] [Related]
18. Development of a novel sustained release formulation of recombinant human growth hormone using sodium hyaluronate microparticles.
Kim SJ; Hahn SK; Kim MJ; Kim DH; Lee YP
J Control Release; 2005 May; 104(2):323-35. PubMed ID: 15907583
[TBL] [Abstract][Full Text] [Related]
19. Alterations of growth plate and abnormal insulin-like growth factor I metabolism in growth-retarded hypokalemic rats: effect of growth hormone treatment.
Gil-Peña H; Garcia-Lopez E; Alvarez-Garcia O; Loredo V; Carbajo-Perez E; Ordoñez FA; Rodriguez-Suarez J; Santos F
Am J Physiol Renal Physiol; 2009 Sep; 297(3):F639-45. PubMed ID: 19587145
[TBL] [Abstract][Full Text] [Related]
20. A reversible albumin-binding growth hormone derivative is well tolerated and possesses a potential once-weekly treatment profile.
Rasmussen MH; Olsen MW; Alifrangis L; Klim S; Suntum M
J Clin Endocrinol Metab; 2014 Oct; 99(10):E1819-29. PubMed ID: 25013997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
